392 results about "Bioavailability" patented technology

This invention discloses a cardioprotective compound composition and its preparation based on improving the absorption rate of coenzyme Q10, relating to the fields of pharmaceuticals and functional foods. The core active ingredients of this composition consist of coenzyme Q10, vitamin E, and black pepper extract, with a specific mass ratio range for each. It can also be combined with pharmaceutically acceptable carriers and antioxidant synergists to prepare various oral formulations. This invention, through the construction of a ternary active component with a specific ratio, achieves in vivo synergistic effects on absorption promotion and antioxidant regeneration, solving the technical problems of low oral bioavailability and insufficient accumulation of myocardial-targeted activity in existing coenzyme Q10 preparations. It significantly improves the conversion efficiency of coenzyme Q10 into a usable active form for cardiomyocytes and can be widely applied in the preparation of drugs and functional foods for the prevention or treatment of heart diseases.

This invention belongs to the fields of biomedicine, beauty, and personal care health technology, and discloses a dual-target oil-controlling peptide co-amorphous assembly, its preparation method, and its application. The method involves adding capryloylglycine and acetyl tetrapeptide-5 to an alcohol solution, heating to dissolve, rotary evaporating, and drying to obtain a co-amorphous compound. This compound is then mixed with a cyclodextrin compound and water, rotary evaporating, and drying to obtain the dual-target oil-controlling peptide co-amorphous assembly. This invention employs a co-amorphous combination with cyclodextrin inclusion to assemble acetyl tetrapeptide-5 and capryloylglycine, solving the problem of their large solubility differences and difficulty in coexistence, and significantly improving the solubility of capryloylglycine. This assembly enables simultaneous transdermal delivery of the two active components through nano-assembly, helping to enhance the stability of acetyl tetrapeptide-5 and reduce its oxidative degradation. The two components synergistically control oil through a dual pathway of inhibiting 5α-reductase and targeting the MC5R receptor, respectively, exhibiting superior bioavailability and efficacy compared to a single component.

The application discloses an oral nano-vaccine and a preparation method and application thereof, and relates to the technical field of immunology, and specifically discloses an oral nano-vaccine which comprises a nano-particle wrapped by a biomimetic bacterial membrane vesicle and an outer layer; the nano-particle comprises an antigen and a biodegradable polymer material; the biomimetic bacterial membrane vesicle comprises an ionizable flagellar lipoprotein, an immune adjuvant, a phospholipid, a sterol lipid and a polyethylene glycol lipid; and the outer layer is a pH-responsive polymer. The oral nano-vaccine provided by the application combines the immune activation advantages of natural bacterial membrane vesicles and the precise regulation characteristics of synthetic materials, significantly improves the transmembrane penetration capacity of the antigen in the intestinal epithelium and the overall activation effect of the mucosal immune system. The oral nano-vaccine provided by the application can protect the antigen and the immune adjuvant from degradation and realize precise release in the intestinal microenvironment; and the oral nano-vaccine significantly improves the bioavailability and safety of an oral tumor vaccine, and lays a key technical foundation for clinical transformation and large-scale production of the oral tumor vaccine.

The present application relates to a pharmaceutical composition comprising an NRF2 agonist and borneol, both of which synergize in a specific molar ratio range, enhance the overall anti-inflammatory and antioxidant biological activity of the drug, improve the oral bioavailability and target tissue distribution of the drug, inhibit the off-target side effects of the NRF2 agonist, and significantly improve the effectiveness and safety of the drug.

This invention belongs to the field of pharmaceutical formulation technology and provides a vinpocetine suspension and its preparation method. The vinpocetine suspension of this invention comprises the following raw materials in specific mass parts: vinpocetine, a suspending agent, a solubilizer, a stabilizer, and water. The vinpocetine suspension of this invention is suitable for oral administration. The excipients in the suspension include a suspending agent, a solubilizer, and a stabilizer. The solubilizer inhibits the aggregation of vinpocetine nanoparticles and improves the solubility and dispersion uniformity of vinpocetine nanoparticles in water. The suspending agent and stabilizer together construct a spatially stable structure, ensuring the suspension and dispersion of vinpocetine nanoparticles and resisting sedimentation. The suspending agent, solubilizer, and stabilizer work synergistically to achieve nanoscale distribution and uniform dispersion and suspension of vinpocetine, significantly improving the bioavailability of vinpocetine. High-pressure homogenization achieves nanoscale distribution of vinpocetine, with a particle size of 200-300 nm.

This invention discloses a multi-target synergistic anti-liver cancer medical food granule and its preparation method. The granule uses medicinal and edible homologous foods and novel resource foods as raw materials, and is composed of curcumin extract, esterified fat-soluble EGCG, Moringa leaf powder, yeast β-glucan, Astragalus extract, Schisandra extract, Salvia miltiorrhiza extract, Poria cocos powder, resistant dextrin, and erythritol in a specific ratio to construct a three-dimensional synergistic system of "direct killing-immune regulation-liver protection," which can induce ferroptosis in liver cancer cells, inhibit protective autophagy, activate the body's immunity, and protect liver cells. This invention employs directional extraction, multi-layer coating, and high-pressure fusion granulation technology. Nanoparticle liposome encapsulation, esterification modification, and pH-responsive enteric coating improve the stability and bioavailability of the components, solving the problems of poor water solubility, low absorption, and easy degradation of natural active ingredients. The granule has clear efficacy, high safety, and stable process, and can be used as a medical food for adjuvant therapy and nutritional support during the recovery period of liver cancer.

This invention discloses the application and method of a STAT1-targeting inhibitor in the treatment of immune thrombocytopenic purpura (ITP). It employs ivermectin, a STAT1 nuclear translocation inhibitor, and fludarabine, a STAT1 activation inhibitor. By injecting either the activation inhibitor or the nuclear translocation inhibitor, the platelet count in a mouse model of ITP is increased. Fludarabine, a fluorinated nucleotide analog of vidarabine, is non-radioactive and a small-molecule phosphorylation inhibitor. Ivermectin is a small-molecule inhibitor of nuclear translocation mediated by α / β1 introgression protein. Both have high bioavailability and are widely used to treat various hematological diseases with good safety profiles. Their application in treating ITP is safe, effective, and shows high compliance.

This application relates to the field of functional composition technology, and in particular to a GABA-vitamin D neuroprotective composition and its preparation method, comprising medium-chain triglycerides, modified phospholipids, and a GABA-vitamin D blend. This application utilizes the low interfacial tension and strong amphiphilic compatibility of medium-chain triglycerides and modified phospholipids, enabling them to be miscible with the blend, thus improving the characteristics of GABA and vitamin D being easily degraded and oxidatively inactivated under complex physiological environments, and solving the problems of poor stability and asynchronous absorption. In the preparation method, the preferred component mass ratio is (0.6–1.5):1:(1–1.6), and mixing is carried out at 50–80°C for 10–60 min. The resulting system features high encapsulation efficiency, uniform particle size distribution, and high bioavailability. After treatment in simulated gastric fluid (pH 1.2) for 2 hours, the average GABA retention rate is ≥88% (optimal up to 94.3%), and the average vitamin D retention rate is ≥94% (optimal up to 96.8%). After treatment in simulated intestinal fluid (pH 6.8) for 4 hours, the simultaneous release rate of GABA and vitamin D is ≥90%, achieving precise intestinal delivery and making it suitable for industrial production.

This invention discloses a lipid nanoparticle co-delivery system based on phenolic hydroxyl lipids and a manganese adjuvant. Addressing the shortcomings of traditional HPV therapeutic peptide vaccines—weak immunogenicity, easy degradation and inactivation in vivo, low bioavailability of manganese ion adjuvants making spatiotemporal co-delivery with antigens, and poor encapsulation efficiency and insufficient biosafety of conventional lipid nanocarriers—this invention constructs an integrated nanovaccine delivery system by embedding phenolic hydroxyl functional lipids into a nanocarrier framework, synergistically loading HPV E6 / E7 specific antigen peptides and manganese ion immune adjuvants. This system achieves efficient delivery, immune activation, and anti-tumor efficacy, integrating the functions of efficient antigen delivery, potent immune activation, and precise anti-tumor action. The preparation process is simple and exhibits excellent stability, overcoming the limitations of traditional HPV peptide vaccines with poor efficacy when used alone. It has broad research value and clinical translation prospects in the field of precision immunotherapy for HPV-related cervical cancer, head and neck squamous cell carcinoma, and other malignant tumors.

The application belongs to the technical field of bioactive nanomaterials, and particularly relates to a metformin nanomaterial, a preparation method and application thereof. The average hydrodynamic diameter of the nanomaterial is less than 500 nm, and the nanomaterial is prepared by a preparation method comprising the following steps: self-assembly of metformin and polyphenols to obtain metformin-polyphenol nanoparticles; reaction of bisphosphonate and polyethylene glycol to obtain bisphosphonate-polyethylene glycol organic segments; and reaction of the metformin-polyphenol nanoparticles and the bisphosphonate-polyethylene glycol organic segments to obtain the nanomaterial. The metformin, polyphenol, polyethylene glycol and bisphosphonate are prepared into the metformin-loaded nanomaterial through specific reactions, the systemic delivery of metformin is realized, the efficacy and bioavailability of metformin on osteoporosis are improved, and the bone targeting of metformin is also improved.

The present invention relates to the crystalline form of bipyrimidine compounds, as well as methods for preparing the same and their use. In particular, the present invention relates to crystalline form I of 4'-cyclopropyl-5,6'-dimethoxy-N-((4-(1-methyl-4-(trifluoromethyl)-1H-imidazole-2-yl)bicyclo[2.2.2]octan-1-yl)methyl)-[2,5'-bipyrimidine]-4-amine, wherein the X-ray powder diffraction pattern of crystalline form I includes characteristic peaks at diffraction angles (2θ) of 6.378±0.2°, 9.521±0.2°, 15.721±0.2°, 16.379±0.2°, 16.981±0.2°, 17.560±0.2°, 19.080±0.2° and 22.200±0.2°. Crystal form I possesses high stability, high solubility, high plasma concentration, high bioavailability, and excellent pharmacological activity, making it suitable for pharmaceutical preparations.

The application provides a glycyrrhetinic acid composition with redness-reducing and anti-inflammatory functions, and a preparation method and application thereof, and belongs to the technical field of cosmetics. Glycyrrhiza is subjected to enzymolysis, supercritical fluid extraction, and precipitation to obtain glycyrrhetinic acid, the glycyrrhetinic acid is coupled with allantoin to obtain a glycyrrhetinic acid-allantoin conjugate, the glycyrrhetinic acid is reacted with menthol to obtain glycyrrhetinic acid menthol ester, the glycyrrhetinic acid-allantoin conjugate, phospholipid and cholesterol are added into ethanol for dissolution, ethanol is removed by rotary evaporation under reduced pressure, a transparent film is obtained, an ethanol solution is added, ultrasonic treatment is carried out, and micro-porous membrane filtration is carried out to obtain the glycyrrhetinic acid composition with the redness-reducing and anti-inflammatory functions. The glycyrrhetinic acid composition with the redness-reducing and anti-inflammatory functions has the effects of redness reduction, anti-allergy, inflammation reduction, antibiosis, soothing, moisturizing and the like, effectively improves the transdermal penetration capacity of active ingredients, improves the water-solubility, greatly improves the bioavailability of the product, and thus expands the application range.

This application belongs to the field of biomedicine, specifically relating to a method for preparing an antitumor composition for pets, aiming to solve the technical problems of low bioavailability, poor stability, and poor drug administration compliance of poorly soluble active ingredients in antitumor drugs for pets. The method includes: a raw material pretreatment step, in which curcumin, resveratrol, quercetin, green tea polyphenols, and astragalus polysaccharides are pulverized and sieved separately; an organic phase preparation step, in which egg yolk lecithin and solid lipids are dissolved in an ethanol-acetone mixed solvent, and curcumin and resveratrol are added and dissolved by stirring in a water bath; an aqueous phase preparation step, in which poloxamer F68 is dissolved in purified water and dissolved in a water bath; a high-pressure homogenization step, in which a nanoemulsion containing a solid lipid core is prepared; a moderately polar component encapsulation step, in which quercetin and green tea polyphenols are ultrasonically dispersed and then added dropwise to the nanoemulsion; a freeze-drying step, in which a nano-lyophilized powder is obtained; and an outer hydrophilic component coating step, in which astragalus polysaccharides are sprayed or adsorbed onto the surface of the freeze-dried powder. The composition obtained by this method is a core-shell multilayer nanoparticle with a core consisting of curcumin and resveratrol encapsulated by solid lipids, a middle shell adsorbing quercetin and green tea polyphenols, and an outer shell coated with astragalus polysaccharides. This application utilizes the above-mentioned layered encapsulation technology to achieve stable co-encapsulation of multiple antitumor active ingredients, improve the bioavailability of poorly soluble components, optimize drug stability, and enhance antitumor effects through multi-target synergistic effects. Simultaneously, it endows the composition with immunomodulatory functions and sustained-release properties. The composition can be formulated into a nano-lyophilized powder form, making it easy to add to pet food or formulate into a paste for administration, improving pet drug compliance. Figure 2 is a schematic diagram of the three-layer core-shell nanoparticle structure of the composition of this invention.

The application discloses a sustained-release preparation of indobufen and a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The application relates to a sustained-release preparation of indobufen and a preparation method and application thereof. The preparation has the characteristics of stable sustained-release effect, high bioavailability, good drug-taking compliance and small side effect, and is suitable for the prevention and / or treatment of diseases such as ischemic cardiovascular diseases, ischemic cerebrovascular diseases and venous thrombosis.

Provided herein are pharmaceutical formulations comprising glucokinase activator, or a prodrug, or a pharmaceutically acceptable salt, an isotope labeled analogue, a crystalline form, a hydrate, a solvate, or a diastereomeric or enantiomeric form thereof and the use thereof for treating diseases; the pharmaceutical formulations are in the form of immediate-release formulations, extended-release formulations, or combination of immediate-release formulation and extended-release formulations. The pharmaceutical formulations achieved once-a-day therapy for some diseases, in particular, type II Diabetes Mellitus with obesity. The pharmaceutical formulations exhibit sustained 24 hours of glucose-lowering effects. The pharmaceutical formulations also achieved lower Cmax, extended T1 / 2 as well as maintained similar bioavailability and increased MRT compared with commercial Dorzagliatin tablet, enhanced the pharmacology effect of restoring the glucose stimulated GLP-1 secretion in diabetes with obesity.

Disclosed is an acylated insulin, a pharmaceutical preparation thereof, a pharmaceutical composition thereof with a long-acting GLP-1 compound, and a medical use of the acylated insulin, the pharmaceutical preparation and the pharmaceutical composition. Compared with insulin degludec or other insulin derivatives, the acylated insulin has an unexpected, significantly increased drug effect, a long duration of action, a long in vivo half-life, an excellent bioavailability, as well as excellent physical and chemical stabilities.

The application relates to the technical field of sialic acid application, in particular to application of sialic acid in promoting iron absorption of iron supplement agents. It is found for the first time that sialic acid with a daily intake of 0.8-3.5 mg / kg and ferrous iron with a daily intake of 0.2-0.5 mg / kg can promote the absorption of ferrous iron by human bodies. More specifically, the application claims an iron supplement agent containing ferrous iron drugs and sialic acid. The iron supplement agent provided by the application promotes iron supplement by compounding sialic acid and ferrous iron drugs, thereby improving the bioavailability of iron, regulating immunity, promoting intestinal health and achieving various biological activities while supplementing iron.

The present invention relates to a syrup containing alectinib or a salt thereof. The present invention provides a syrup containing alectinib or a salt thereof, which is a poorly water soluble agent, and having improved fluidity and / or palatability. The syrup of the present invention has a plasma concentration profile equivalent to or greater than, or is biologically equivalent to, a capsule containing the same amount of alectinib or a salt thereof as the syrup, or has an enhanced oral bioavailability compared to a capsule containing the same amount of alectinib or a salt thereof as the syrup.

The application relates to a corneal drug delivery scleral lens, which comprises a lens body, the lens body comprises a treatment area, a reverse area and a landing area from the center to the outside, the treatment area is located in the center, the reverse area is arranged around the treatment area and is used for connecting the treatment area and the landing area, the landing area is arranged around the reverse area and is used for supporting a scleral surface, so that a liquid accumulation layer is formed between a corneal front surface and the lens body; a flow guide pipe is arranged in the lens body in the radial direction, forming a liquid injection end and a drug delivery hole. The scleral lens of the application can supplement liquid medicine through the flow guide pipe without taking off the lens, dynamic fluid replacement is realized, and the cornea is prevented from being damaged by repeated taking off and wearing. When the lens is designed, the height of the reverse area is taken as a core variable parameterization design, the thickness of the liquid accumulation area and the drug concentration are accurately controlled. The overflow hole is normally sealed, and the risk of infection is reduced. The liquid medicine is diffused from the edge to the center, the whole surface of the cornea is uniformly soaked, and the bioavailability is improved.

The invention relates to application of graphene-(RADA-IKVAV)-pranoprofen, eye drops and a preparation method of the eye drops. The invention relates to graphene-(RADA-IKVAV)-pranoprofen, the graphene-(RADA-IKVAV)-pranoprofen comprises graphene-polyacrylic acid, self-assembled oligopeptide RADA-IKVAV and pranoprofen, the self-assembled oligopeptide RADA-IKVAV is connected with the graphene-polyacrylic acid through a chemical bond, and the pranoprofen is loaded on the surface of the graphene-polyacrylic acid. The eye drops provided by the invention comprise graphene-(RADA-IKVAV)-pranoprofen, so that the drug loading capacity of pranoprofen in the eye drops is increased, the bioavailability of drugs is improved, and the eye drops are used for inhibiting eye inflammation; the coupled oligopeptide RADA-IKVAV simulates an extracellular environment, provides a suitable microenvironment for eyes, promotes nerve repair and regeneration by influencing nerve growth factors, and promotes optic nerve repair.

This invention discloses a Zhishu Yangwei tablet for chronic gastritis and its granule dry-compression tableting process, relating to the field of traditional Chinese medicine preparation technology. The Yangwei tablet is made from the following raw materials in parts by weight: Codonopsis pilosula 35-45 parts, stir-fried Atractylodes macrocephala 18-22 parts, Poria cocos 18-22 parts, Glycyrrhiza uralensis 8-12 parts, Amomum villosum 18-22 parts, Lindera strychnifolia 18-22 parts, Salvia miltiorrhiza 45-55 parts, roasted Aucklandia lappa 18-22 parts, Paeonia lactiflora 18-22 parts, stir-fried Citrus aurantium 18-22 parts, Magnolia officinalis 28-32 parts, Lilium brownii 35-45 parts, and stir-fried chicken gizzard lining 18- 22 parts, dried plum 45-55 parts, Coptis chinensis 8-12 parts, hawthorn 35-45 parts, magnesium stearate 5-7 parts, sucrose 28-32 parts; This invention uses low-temperature dynamic extraction technology to replace the traditional high-temperature decoction process, effectively reducing the decomposition loss of heat-sensitive active ingredients such as tanshinone IIA and ursolic acid, and improving the bioavailability of the drug. It also uses membrane concentration and spray drying technology to replace the traditional atmospheric pressure concentration and oven drying process, shortening the production cycle, reducing energy consumption, and avoiding the degradation of active ingredients caused by prolonged heating of materials.

The present application relates to the technical field of medicine, and particularly relates to a drug composition with a sequential synergistic repair effect and a preparation method and application thereof. The drug composition comprises liposome I encapsulating caffeic acid and liposome II encapsulating BH4; the liposome I is a ROS-responsive liposome, can specifically respond in a high ROS microenvironment, and then realize on-demand release of caffeic acid; meanwhile, the liposome II protects BH4 from entering cells to play a role, can effectively overcome the defects of difficult dissolution of caffeic acid and easy oxidation of caffeic acid and BH4, can improve the bioavailability of the two drugs, can realize sequential release of caffeic acid and BH4, and can play a synergistic treatment effect on different mechanisms of occurrence of radioactive skin damage, and provides a sequential synergistic repair strategy for clinic. The liposome I and the liposome II are both prepared by a thin film hydration method, and the operation is simple, the conditions are mild, the lipid film is uniformly formed, and the encapsulation rates of caffeic acid and BH4 are high.

The sustained-release formulation of this invention, with its increased initial release, exhibits a rapid release effect within 24 hours after administration, followed by a sustained-release effect, thus simultaneously achieving both prolonged efficacy and rapid initial release. The sustained-release formulation of this invention, containing microspheres of leuprorelin, possesses excellent bioavailability and has been proven safe in humans; therefore, it can be effectively and safely used to treat various luteinizing hormone-releasing hormone-related diseases such as endometriosis, uterine fibroids, prostate cancer, premenopausal breast cancer, and central precocious puberty.

The present application relates to the technical field of disease detection, and more particularly to a method for diagnosing and treating early atherosclerotic plaques based on multifunctional nanomaterial CeOx-P@PM, which comprises the following steps: S1: assembling CeOx with a MMP2 specific probe to form a CeOx-P compound; and S2: coating the CeOx-P compound with a biomimetic platelet membrane as a carrier to assemble CeOx-P@PM nanoparticles. The method for diagnosing and treating early atherosclerotic plaques based on multifunctional nanomaterial CeOx-P@PM has the excellent characteristics of efficient ROS removal, high bioavailability, lesion targeting, and dual-mode precise imaging, and will provide great help for the diagnosis and treatment of early atherosclerotic plaques in clinical practice.

The application belongs to the technical field of pharmaceutical chemistry, and particularly relates to clofazimine-organic acid co-crystals, a preparation method and application thereof. The clofazimine-organic acid co-crystal is one of clofazimine-ferulic acid monohydrate co-crystal, clofazimine-ferulic acid co-crystal, clofazimine-glutaric acid co-crystal, clofazimine-glycolic acid co-crystal (CFZ-GA 1:1), clofazimine-glycolic acid co-crystal (CFZ-GA 1:1.5), clofazimine-salicylic acid co-crystal, clofazimine-L-aspartic acid co-crystal, clofazimine-L-pyroglutamic acid co-crystal, clofazimine-gallic acid co-crystal, clofazimine-succinic acid co-crystal, clofazimine-tartaric acid co-crystal and clofazimine-DL-mandelic acid co-crystal. The clofazimine-organic acid co-crystal provided by the application significantly improves the solubility and fluidity of clofazimine, thereby improving the bioavailability of clofazimine, and has a broad medicinal prospect.

The present disclosure relates to the field of drug delivery, in particular, the present disclosure relates to a microneedle drug delivery device and a preparation method thereof. The device comprises a substrate, a microneedle array and a liquid-absorbing swelling material, the substrate carries the microneedle array, and the liquid-absorbing swelling material is arranged between the substrates to form a sandwich structure. The device uses a mild water-absorbing swelling mechanism and the natural peristalsis of the gastrointestinal tract to pierce the microneedles into the intestinal wall, complete drug delivery, physically break through the physiological barrier of oral delivery and absorption of biological drugs, and improve the oral bioavailability of biological drugs. The materials used are all biodegradable soft materials, which are safe.

In the present invention it has been found a pharmaceutical formulation comprising a GLP-1 peptide agonist; a C6-C9 fatty acid or a salt thereof or a combination of a C6- C9 fatty acid or a salt thereof and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid as the sole permeability enhancers can be used to increase the bioavailability of the peptide in the formulation. The salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and the C6-C9 fatty acid each act as permeability enhancers, and improve the bioavailability of the peptide. The pharmaceutical formulation can be used in the treatment of diabetes mellitus and obesity.

This invention discloses a pharmaceutical composition and its preparation method for treating atrophic gastritis, precancerous lesions of the stomach, and stomach cancer, belonging to the field of traditional Chinese medicine preparation technology. The pharmaceutical composition is prepared by a specific two-step microbial fermentation process using Astragalus membranaceus, Hericium erinaceus, Curcuma zedoaria, Actinidia chinensis root, Camptotheca acuminata fruit, Hedyotis diffusa, Coptis chinensis, Taraxacum mongolicum, Viola yedoensis, Corydalis yanhusuo (processed with vinegar), Phellodendron chinense, Solanum nigrum, Scutellaria baicalensis, Panax notoginseng, Zingiber officinale, Piper cubeba, Cuttlebone, Fritillaria thunbergii, roasted soybean, and red yeast rice. This invention significantly improves the bioavailability of the active pharmaceutical ingredients through the synergistic effect of the multifunctional groups of traditional Chinese medicine and the enhanced effect of microbial fermentation. It can systematically reverse gastric mucosal atrophy and intestinal metaplasia, effectively improve microcirculation, and inhibit Helicobacter pylori, while also exhibiting good safety. This provides a novel and effective treatment for the aforementioned gastric diseases.

The present application relates to the technical field of traditional Chinese medicine preparation, and discloses a plant extract composition for relieving liver-QI stagnation and nodules, which is made of isomaltooligosaccharide, matrix precursor liquid derived from kelp and licorice, lipophilic concentrate, natural organic acid adjusting liquid and heat-sensitive active liquid. By in-situ reaction of the matrix precursor liquid and the organic acid, an interpenetrating network structure of glycyrrhizic acid and alginic acid is constructed in the system, and an oil-in-water emulsion gel with thixotropy and pH responsiveness is formed. The preparation method comprises matrix emulsification, organic acid atomization instantaneous initiation, low-temperature composite heat-sensitive component and double-stage cooling shaping. The present application realizes targeted enteric release of the drug by the interpenetrating network, and protects the heat-sensitive component, thus solving the problems of poor stability and low bioavailability of traditional preparations, and having the effects of soothing the liver and regulating Qi, softening and resolving nodules, and strengthening the body resistance.

The disclosed invention relates to the use of digestion-resistant maltodextrin soluble fibers to enhance and sustain the bioavailability of biologically and pharmaceutically active components by acting as a prebiotic digestive modulator for the active components, as well as compositions containing those components.